DelveInsight’s “Rosacea Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Rosacea market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Rosacea drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Rosacea treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Rosacea: An Overview
Rosacea is a characteristic condition that affects the skin by causing facial erythema or redness. Around one in 10 people in the world is affected by rosacea. There are four types of rosacea, though many people experience symptoms of more than one type.
Erythematotelangiectatic Rosacea, Papulopustular Rosacea, Phymatous Rosacea, and Ocular Rosacea are the four types of Rosacea. Due to the complexity of the disease with its heterogeneous appearance, classification is subject to constant change. Therefore, no international consensus has been established as yet.
Researchers found that the disease runs in families and may be caused due to the immune reaction against bacillus oleronius, H. pylori infection, cathelicidin protein, or due to a mite that lives on the skin. The disease diagnosis is based on a compatible history and physical examination. The patient may be misdiagnosed with skin conditions that share similar features as adult acne vulgaris, photodermatitis, seborrheic dermatitis, or contact dermatitis.
There is no cure for rosacea except for symptomatic management. Oral antibiotics used in Rosacea include minocycline, doxycycline, erythromycin, clarithromycin, and clindamycin. The goal of oral therapy is to improve the rosacea to a point where control is achieved by topical therapies.
Rosacea Market Key Facts
-
As per the article by Mandal (n.d.), titled “Rosacea Epidemiology,” in the United States, the prevalence of rosacea seems to be on the rise, and in the United Kingdom, the prevalence is 1.65 per 1000 person-years. There is a paucity of epidemiological data on rosacea, with reported prevalence rates ranging from as little as 0.09% to as much as 22.00%.
-
In recent surveys by the National Rosacea Society, nearly 70% of rosacea patients said this condition had lowered their self-confidence and self-esteem, and 41% reported it had caused them to avoid public contact or cancel social engagements. It has been reported in studies that Rosacea affects Quality of Life.
-
As per the article by Reinholz et al. (2016), titled “Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy,” a German registry study with a cohort of 90,880 office employees showed a prevalence of 2.3%.
-
As per the article by Mandal (n.d.), titled “Rosacea Epidemiology,” in the United States, the prevalence of rosacea seems to be on the rise, and in the United Kingdom, the prevalence is 1.65 per 1000 person-years. There is a paucity of epidemiological data on rosacea, with reported prevalence rates ranging from as little as 0.09% to as much as 22.00%.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Rosacea pipeline therapies. It also thoroughly assesses the Rosacea market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Rosacea drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Rosacea Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Rosacea epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Rosacea epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Rosacea Epidemiology, Segmented as –
-
Total Prevalent Population of Rosacea
-
Gender-specific Prevalent Population of Rosacea
-
Diagnosed and Treatable Prevalence of Rosacea
-
Subtype-specific Diagnosed Prevalence of Rosacea
-
Severity-specific Diagnosed Prevalence of Rosacea
Rosacea Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Rosacea market or expected to be launched during the study period. The analysis covers the Rosacea market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Rosacea drugs based on their sale and market share.
The report also covers the Rosacea pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Rosacea companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Rosacea Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/rosacea-market
Rosacea Therapeutics Analysis
The current therapeutic landscape of Rosacea can be divided into four major categories based on the route of administration and the approved usage for the condition. These are topical retinoids, topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids.
For moderate papulopustular rosacea, combination therapy with oral tetracyclines and topical agents is the first-line choice. Treatment with a topical agent, such as metronidazole, may help maintain remission.
Among Topical therapies, topical retinoids mainly include Tretinoin, Tazarotene, Adapalene, and Clindamycin/tretinoin, and several others are used to reduce erythema, papules and pustules, and telangiectasias. Among these, Tretinoin has the lowest cost and most commonly prescribed topical retinoid, accounting for the majority of the population.
Several major pharma and biotech companies are developing therapies for Rosacea. Currently, Sol-Gel Technologies is leading the therapeutics market with its Rosacea drug candidates in the most advanced stage of clinical development.
Rosacea Companies Actively Working in the Therapeutics Market Include
-
AiViva BioPharma
-
Alfasigma
-
Amgen
-
AOBiome
-
AOBiome LLC
-
BioMimetix JV, LLC
-
BioPharmX, Inc.
-
Botanix Pharmaceuticals
-
CAGE Bio Inc.
-
Cellix Bio.
-
Dermata Therapeutics
-
Dr Reddys Laboratories
-
Evommune
-
Fortress Biotech
-
Maruho Co., Ltd.
-
Sol-Gel Technologies
-
Tarus Pharmaceuticals
And Many Others
Emerging and Marketed Rosacea Therapies Covered in the Report Include:
-
Epsolay: Sol-Gel Technologies
-
M 1220: Maruho Ltd.,
-
BMX-010: BioMimetix
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/rosacea-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Rosacea Competitive Intelligence Analysis
4. Rosacea Market Overview at a Glance
5. Rosacea Disease Background and Overview
6. Rosacea Patient Journey
7. Rosacea Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Rosacea Treatment Algorithm, Current Treatment, and Medical Practices
9. Rosacea Unmet Needs
10. Key Endpoints of Rosacea Treatment
11. Rosacea Marketed Therapies
12. Rosacea Emerging Drugs and Latest Therapeutic Advances
13. Rosacea Seven Major Market Analysis
14. Attribute Analysis
15. Rosacea Market Outlook (In US, EU5, and Japan)
16. Rosacea Companies Active in the Market
17. Rosacea Access and Reimbursement Overview
18. KOL Views on the Rosacea Market
19. Rosacea Market Drivers
20. Rosacea Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/rosacea-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“IgA Nephropathy (IgAN) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the IgA Nephropathy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the IgAN market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices